Toll Like Receptor 3 (CD283 or TLR3) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Toll Like Receptor 3 (CD283 or TLR3) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
Toll Like Receptor 3 (CD283 or TLR3) - Toll-like receptor 3 (TLR3) is a protein encoded by the TLR3 gene. It controls host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. It acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion and the inflammatory response.
Toll Like Receptor 3 (CD283 or TLR3) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 1, 1, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Report covers products from therapy areas Oncology, Infectious Disease, Central Nervous System, Gastrointestinal, Immunology and Respiratory which include indications Coronavirus Disease 2019 (COVID-19), Melanoma, Epithelial Ovarian Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Metastatic Colorectal Cancer, Peritoneal Cancer, Unspecified Cancer, Acute Inflammation, Bladder Cancer, Breast Cancer, Chronic Fatigue Syndrome (Myalgic Encephalomyelitis), Chronic Inflammation, Cognitive Disorders, Colon Cancer, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Fallopian Tube Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatitis B, Hepatocellular Carcinoma, Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer), Influenza A Virus, H3N2 Subtype Infections, Kidney Cancer (Renal Cell Cancer), Malignant Pleural Mesothelioma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Pancreatic Cancer, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Prostate Cancer, Pulmonary Inflammation, Renal Cell Carcinoma, Rhinovirus Infections, Sarcomas, Severe Acute Respiratory Syndrome (SARS), Soft Tissue Sarcoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Triple-Negative Breast Cancer (TNBC).
The latest report Toll Like Receptor 3 - Drugs In Development, 2022, outlays comprehensive information on the Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Toll Like Receptor 3 (CD283 or TLR3) - Toll-like receptor 3 (TLR3) is a protein encoded by the TLR3 gene. It controls host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. It acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion and the inflammatory response.
Toll Like Receptor 3 (CD283 or TLR3) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 1, 1, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Report covers products from therapy areas Oncology, Infectious Disease, Central Nervous System, Gastrointestinal, Immunology and Respiratory which include indications Coronavirus Disease 2019 (COVID-19), Melanoma, Epithelial Ovarian Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Metastatic Colorectal Cancer, Peritoneal Cancer, Unspecified Cancer, Acute Inflammation, Bladder Cancer, Breast Cancer, Chronic Fatigue Syndrome (Myalgic Encephalomyelitis), Chronic Inflammation, Cognitive Disorders, Colon Cancer, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Fallopian Tube Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatitis B, Hepatocellular Carcinoma, Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer), Influenza A Virus, H3N2 Subtype Infections, Kidney Cancer (Renal Cell Cancer), Malignant Pleural Mesothelioma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Pancreatic Cancer, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Prostate Cancer, Pulmonary Inflammation, Renal Cell Carcinoma, Rhinovirus Infections, Sarcomas, Severe Acute Respiratory Syndrome (SARS), Soft Tissue Sarcoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Triple-Negative Breast Cancer (TNBC).
The latest report Toll Like Receptor 3 - Drugs In Development, 2022, outlays comprehensive information on the Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 3 (CD283 or TLR3)
- The report reviews Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 3 (CD283 or TLR3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 3 (CD283 or TLR3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Toll Like Receptor 3 (CD283 or TLR3) - Overview
Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toll Like Receptor 3 (CD283 or TLR3) - Companies Involved in Therapeutics Development
13therapeutics Inc
AIM ImmunoTech Inc
Aston Sci Co Ltd
Glysantis Inc
HDT Bio Corp
Highlight Therapeutics SL
Oncovir Inc
PrEP Biopharm Ltd
Tollys SAS
Wyvern Pharmaceuticals Inc
Yisheng Biopharma Co Ltd
Toll Like Receptor 3 (CD283 or TLR3) - Drug Profiles
Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases - Drug Profile
Product Description
Mechanism Of Action
AST-065 - Drug Profile
Product Description
Mechanism Of Action
BO-112 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GLY-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HDT-401 - Drug Profile
Product Description
Mechanism Of Action
History of Events
P-7 - Drug Profile
Product Description
Mechanism Of Action
Poly-ICLC - Drug Profile
Product Description
Mechanism Of Action
History of Events
PrEP-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
rintatolimod - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Antagonize TLR-3 for Gastrointestinal Syndrome - Drug Profile
Product Description
Mechanism Of Action
TL-532 - Drug Profile
Product Description
Mechanism Of Action
History of Events
WYV-ONC - Drug Profile
Product Description
Mechanism Of Action
YSHBV-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Toll Like Receptor 3 (CD283 or TLR3) - Dormant Products
Toll Like Receptor 3 (CD283 or TLR3) - Discontinued Products
Toll Like Receptor 3 (CD283 or TLR3) - Product Development Milestones
Featured News & Press Releases
Mar 09, 2022: AIM ImmunoTech announces abstract from university of Pittsburgh medical center accepted for presentation at the AACR 2022 annual meeting
Mar 09, 2022: AIM ImmunoTech announces abstracts from Roswell Park Comprehensive Cancer Center accepted for presentation in a late-breaking poster session at the AACR 2022 annual meeting
Mar 08, 2022: AIM ImmunoTech announces publication of positive data from late-stage pancreatic cancer Early Access Program (EAP) in the cancers special issue: combination and innovative therapies for Pancreatic Cancer
Jan 24, 2022: AIM ImmunoTech announces publication of positive results from phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer
Dec 09, 2021: AIM ImmunoTech’s Ampligen safety data presented at Eighth European Scientific Working Group on Influenza
Dec 02, 2021: Highlight Therapeutics & Cima announce positive results from pre-clinical study combining BO112 + STING agonist published in Journal for ImmunoTherapy of Cancer
Nov 12, 2021: Positive phase 2b results in 2nd line melanoma
Oct 19, 2021: AIM ImmunoTech submits IND and accompanying fast track application for phase 2 trial of Ampligen in patients with locally advanced or metastatic late-stage pancreatic cancer
Oct 06, 2021: AIM ImmunoTech publishes phase 1 clinical study data supporting the safety of Ampligen as an intranasal therapy
Oct 04, 2021: AIM ImmunoTech provides clinical updates on planned phase 2 study of Ampligen in patients with locally advanced or metastatic late-stage pancreatic cancer
Sep 29, 2021: AIM seeks FDA approval to conduct Phase II Covid-19 therapy trials
Sep 27, 2021: AIM ImmunoTech files provisional patent application for Ampligen as an early-onset intranasal therapy that may also confer enhanced immunity to a wide range of respiratory viruses
Sep 21, 2021: AIM ImmunoTech announces positive progress on requested FDA meeting for proposed Ampligen clinical trial in post-COVID-19 cognitive dysfunction
Sep 20, 2021: AIM ImmunoTech provides an update on its pending phase 2a human challenge trial using its drug Ampligen
Sep 09, 2021: AIM seeks FDA approval for Phase II trial of Ampligen for Covid-19
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Toll Like Receptor 3 (CD283 or TLR3) - Overview
Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toll Like Receptor 3 (CD283 or TLR3) - Companies Involved in Therapeutics Development
13therapeutics Inc
AIM ImmunoTech Inc
Aston Sci Co Ltd
Glysantis Inc
HDT Bio Corp
Highlight Therapeutics SL
Oncovir Inc
PrEP Biopharm Ltd
Tollys SAS
Wyvern Pharmaceuticals Inc
Yisheng Biopharma Co Ltd
Toll Like Receptor 3 (CD283 or TLR3) - Drug Profiles
Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases - Drug Profile
Product Description
Mechanism Of Action
AST-065 - Drug Profile
Product Description
Mechanism Of Action
BO-112 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GLY-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HDT-401 - Drug Profile
Product Description
Mechanism Of Action
History of Events
P-7 - Drug Profile
Product Description
Mechanism Of Action
Poly-ICLC - Drug Profile
Product Description
Mechanism Of Action
History of Events
PrEP-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
rintatolimod - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Antagonize TLR-3 for Gastrointestinal Syndrome - Drug Profile
Product Description
Mechanism Of Action
TL-532 - Drug Profile
Product Description
Mechanism Of Action
History of Events
WYV-ONC - Drug Profile
Product Description
Mechanism Of Action
YSHBV-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Toll Like Receptor 3 (CD283 or TLR3) - Dormant Products
Toll Like Receptor 3 (CD283 or TLR3) - Discontinued Products
Toll Like Receptor 3 (CD283 or TLR3) - Product Development Milestones
Featured News & Press Releases
Mar 09, 2022: AIM ImmunoTech announces abstract from university of Pittsburgh medical center accepted for presentation at the AACR 2022 annual meeting
Mar 09, 2022: AIM ImmunoTech announces abstracts from Roswell Park Comprehensive Cancer Center accepted for presentation in a late-breaking poster session at the AACR 2022 annual meeting
Mar 08, 2022: AIM ImmunoTech announces publication of positive data from late-stage pancreatic cancer Early Access Program (EAP) in the cancers special issue: combination and innovative therapies for Pancreatic Cancer
Jan 24, 2022: AIM ImmunoTech announces publication of positive results from phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer
Dec 09, 2021: AIM ImmunoTech’s Ampligen safety data presented at Eighth European Scientific Working Group on Influenza
Dec 02, 2021: Highlight Therapeutics & Cima announce positive results from pre-clinical study combining BO112 + STING agonist published in Journal for ImmunoTherapy of Cancer
Nov 12, 2021: Positive phase 2b results in 2nd line melanoma
Oct 19, 2021: AIM ImmunoTech submits IND and accompanying fast track application for phase 2 trial of Ampligen in patients with locally advanced or metastatic late-stage pancreatic cancer
Oct 06, 2021: AIM ImmunoTech publishes phase 1 clinical study data supporting the safety of Ampligen as an intranasal therapy
Oct 04, 2021: AIM ImmunoTech provides clinical updates on planned phase 2 study of Ampligen in patients with locally advanced or metastatic late-stage pancreatic cancer
Sep 29, 2021: AIM seeks FDA approval to conduct Phase II Covid-19 therapy trials
Sep 27, 2021: AIM ImmunoTech files provisional patent application for Ampligen as an early-onset intranasal therapy that may also confer enhanced immunity to a wide range of respiratory viruses
Sep 21, 2021: AIM ImmunoTech announces positive progress on requested FDA meeting for proposed Ampligen clinical trial in post-COVID-19 cognitive dysfunction
Sep 20, 2021: AIM ImmunoTech provides an update on its pending phase 2a human challenge trial using its drug Ampligen
Sep 09, 2021: AIM seeks FDA approval for Phase II trial of Ampligen for Covid-19
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by 13therapeutics Inc, 2022
Pipeline by AIM ImmunoTech Inc, 2022
Pipeline by Aston Sci Co Ltd, 2022
Pipeline by Glysantis Inc, 2022
Pipeline by HDT Bio Corp, 2022
Pipeline by Highlight Therapeutics SL, 2022
Pipeline by Oncovir Inc, 2022
Pipeline by PrEP Biopharm Ltd, 2022
Pipeline by Tollys SAS, 2022
Pipeline by Wyvern Pharmaceuticals Inc, 2022
Pipeline by Yisheng Biopharma Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Discontinued Products, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by 13therapeutics Inc, 2022
Pipeline by AIM ImmunoTech Inc, 2022
Pipeline by Aston Sci Co Ltd, 2022
Pipeline by Glysantis Inc, 2022
Pipeline by HDT Bio Corp, 2022
Pipeline by Highlight Therapeutics SL, 2022
Pipeline by Oncovir Inc, 2022
Pipeline by PrEP Biopharm Ltd, 2022
Pipeline by Tollys SAS, 2022
Pipeline by Wyvern Pharmaceuticals Inc, 2022
Pipeline by Yisheng Biopharma Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Discontinued Products, 2022
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
